Retraction
SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
Paper Information
Record ID:
58036
Author(s):
Journal:
Publication Date:
September 04, 2015
Retraction Date:
October 22, 2024
(1.1 year years ago)
Subjects:
Institutions:
- LeBow Institute for Myeloma Therapeutics and the Jerome Lipper Center for Multiple Myeloma Research, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
- Department of Hematology, Myeloma and Lymphoma Centre, Chang Zheng Hospital, The Second Military Medical University, Shanghai, China
- Sanofi Oncology, Cambridge, MA, USA
- Institute of Hematology, CAMS & PUMC, Tianjin, China
Countries:
Article Type:
Publisher:
Springer - Nature Publishing Group
Open Access:
Yes
DOI:
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.1038/s41375-024-02443-zAdditional Notes:
see also: https://pubpeer.com/publications/BE119832A5B1091025C04244B43F5D
Citations (213)
213
Total Citations5
Post-Retraction(2.3%)
208
Pre-Retraction0
Same DayPost-Retraction Citation Analysis
2
Within 30 days
5
Within 1 year
0
After 2+ years
204
Days since retraction (latest)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. (100 authors)
The Lancet
Published: Nov 2019
573 citations
573 citations
1804 days before retraction
Biological Background of Resistance to Current Standards of Care in Multiple Myeloma
Pedro Mogollón, Andrea Díaz-Tejedor, Esperanza M. Algarín et al. (6 authors)
Cells
Open Access
Published: Nov 2019
28 citations
28 citations
1805 days before retraction
In vivo vaccination effect in multiple myeloma patients treated with the monoclonal antibody isatuximab
Djordje Atanackovic, Sara Yousef, Christa Shorter et al. (13 authors)
Leukemia
Published: Aug 2019
35 citations
35 citations
1897 days before retraction
B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma
Yu‐Tzu Tai, Kenneth C. Anderson
Expert Opinion on Biological Therapy
Open Access
Published: Jul 2019
89 citations
89 citations
1935 days before retraction
Novel targets for the treatment of relapsing multiple myeloma
Nicola Giuliani, Fabrizio Accardi, Valentina Marchica et al. (8 authors)
Expert Review of Hematology
Published: May 2019
25 citations
25 citations
1978 days before retraction
Novel anti-CD38 humanized mAb SG003 possessed enhanced cytotoxicity in lymphoma than Daratumumab via antibody-dependent cell-mediated cytotoxicity
Tao Yu, Chunxia Qiao, Ming Lv et al. (4 authors)
BMC Biotechnology
Open Access
Published: May 2019
2 citations
2 citations
1980 days before retraction
Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization
Vadim Le Joncour, Pauliina Filppu, Maija Hyvönen et al. (14 authors)
EMBO Molecular Medicine
Open Access
Published: May 2019
49 citations
49 citations
1994 days before retraction
Elucidation of the cell signaling pathways mediating innate immunity and host-pathogen interactions
Neel R. Nabar
Unknown Journal
Published: Mar 2019
2049 days before retraction
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma
Joseph Mıkhael, Paul G. Richardson, Saad Z. Usmani et al. (12 authors)
Blood
Open Access
Published: Mar 2019
86 citations
86 citations
2051 days before retraction
HLA class II antibodies induce necrotic cell death in human endothelial cells via a lysosomal membrane permeabilization-mediated pathway
Abid Aljabri, Vijith Vijayan, Metodi V. Stankov et al. (9 authors)
Cell Death and Disease
Open Access
Published: Mar 2019
20 citations
20 citations
2055 days before retraction
Augmentation of Saporin-Based Immunotoxins for Human Leukaemia and Lymphoma Cells by Triterpenoid Saponins: The Modifying Effects of Small Molecule Pharmacological Agents
Wendy S. Smith, David A. Johnston, Suzanne E. Holmes et al. (6 authors)
Toxins
Open Access
Published: Feb 2019
8 citations
8 citations
2071 days before retraction
The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Laura Moreno, Cristina Pérez, Aintzane Zabaleta et al. (20 authors)
Clinical Cancer Research
Open Access
Published: Jan 2019
194 citations
194 citations
2094 days before retraction
Novel Agents in Multiple Myeloma
Raphaël Szalat, Nikhil Munshi
The Cancer Journal
Open Access
Published: Jan 2019
27 citations
27 citations
2121 days before retraction
Reprint of “Immunomodulatory effects of CD38-targeting antibodies”
Niels W.C.J. van de Donk
Immunology Letters
Published: Jan 2019
15 citations
15 citations
2121 days before retraction
Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update
H. N. Abramson
International Journal of Molecular Sciences
Open Access
Published: Dec 2018
55 citations
55 citations
2146 days before retraction
Paper citing SAR650984 directly induces multiple myeloma cell d...
Unknown Authors
Unknown Journal
Published: Dec 2018
2146 days before retraction
CD38: A Target for Immunotherapeutic Approaches in Multiple Myeloma
Fabio Morandi, Alberto L. Horenstein, Federica Costa et al. (6 authors)
Frontiers in Immunology
Open Access
Published: Nov 2018
159 citations
159 citations
2155 days before retraction
CD38 as an immunotherapeutic target in multiple myeloma
Francesca Bonello, Mattia D’Agostino, Maria Moscvin et al. (6 authors)
Expert Opinion on Biological Therapy
Published: Nov 2018
44 citations
44 citations
2178 days before retraction
Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update
H. N. Abramson
Unknown Journal
Open Access
Published: Oct 2018
19 citations
19 citations
2190 days before retraction
Therapeutic antibodies for multiple myeloma
Tadao Ishida
Japanese Journal of Clinical Oncology
Open Access
Published: Oct 2018
13 citations
13 citations
2205 days before retraction
CD38 Antibodies in Multiple Myeloma: Mechanisms of Action and Modes of Resistance
Niels W.C.J. van de Donk, Saad Z. Usmani
Frontiers in Immunology
Open Access
Published: Sep 2018
298 citations
298 citations
2224 days before retraction
Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1
Yu‐Tzu Tai, Shih‐Feng Cho, Kenneth C. Anderson
Frontiers in Immunology
Open Access
Published: Aug 2018
56 citations
56 citations
2265 days before retraction
Typical and Atypical Inducers of Lysosomal Cell Death: A Promising Anticancer Strategy
Antoni Domagała, Klaudyna Fidyt, Małgorzata Bobrowicz et al. (6 authors)
International Journal of Molecular Sciences
Open Access
Published: Aug 2018
77 citations
77 citations
2274 days before retraction
Practical Considerations for Antibodies in Myeloma
Jacob P. Laubach, Niels W.C.J. van de Donk, Faith E. Davies et al. (4 authors)
American Society of Clinical Oncology Educational Book
Published: May 2018
13 citations
13 citations
2366 days before retraction
Immunomodulatory effects of CD38-targeting antibodies
Niels W.C.J. van de Donk
Immunology Letters
Published: Apr 2018
79 citations
79 citations
2372 days before retraction
Monoclonal Antibodies
Christian Klein, Susan H. Tam, Stephen McCarthy et al. (47 authors)
MDPI eBooks
Open Access
Published: Apr 2018
4 citations
4 citations
2374 days before retraction
Vulnerability of invasive glioma cells to lysosomal membrane instabilization
Vadim Le Joncour, Maija Hyvönen, Pauliina Filppu et al. (12 authors)
bioRxiv (Cold Spring Harbor Laboratory)
Open Access
Published: Mar 2018
2423 days before retraction
CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience
Kristine A. Frerichs, Noémi Nagy, Pieter L. Lindenbergh et al. (15 authors)
Expert Review of Clinical Immunology
Published: Feb 2018
37 citations
37 citations
2435 days before retraction
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design
Paul G. Richardson, Michel Attal, Frank Campana et al. (8 authors)
Future Oncology
Open Access
Published: Dec 2017
69 citations
69 citations
2496 days before retraction
Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies
Shaji Kumar
Hematology
Open Access
Published: Dec 2017
27 citations
27 citations
2510 days before retraction
Targeting CD38 alleviates tumor-induced immunosuppression
Yu‐Tzu Tai, Kenneth C. Anderson
Oncotarget
Open Access
Published: Dec 2017
26 citations
26 citations
2511 days before retraction
Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
Shih‐Feng Cho, Liang Lin, Lijie Xing et al. (7 authors)
Antibodies
Open Access
Published: Nov 2017
14 citations
14 citations
2534 days before retraction
Natural Cyclopeptide RA-XII, a New Autophagy Inhibitor, Suppresses Protective Autophagy for Enhancing Apoptosis through AMPK/mTOR/P70S6K Pathways in HepG2 Cells
Lihua Song, Zhe Wang, Yurong Wang et al. (7 authors)
Molecules
Open Access
Published: Nov 2017
47 citations
47 citations
2537 days before retraction
CD38 antibodies in multiple myeloma: back to the future
Niels W.C.J. van de Donk, Paul G. Richardson, Fabio Malavasi
Blood
Open Access
Published: Nov 2017
417 citations
417 citations
2540 days before retraction
Transfusion Practices in the Era of Anti-CD38 Antibodies in the Treatment of Multiple Myeloma: A Mini Review
Ruemu Birhiray
Unknown Journal
Open Access
Published: Oct 2017
1 citation
1 citation
2551 days before retraction
Daratumumab combinations: what can we learn?
Efstathios Kastritis, Meletios Α. Dimopoulos
Blood
Open Access
Published: Aug 2017
4 citations
4 citations
2616 days before retraction
Immunotherapy in Multiple Myeloma
Charise Gleason, Donna Catamero
Seminars in Oncology Nursing
Published: Jul 2017
3 citations
3 citations
2647 days before retraction
Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today’s treat-to-target era
Li Zhang, Yu‐Tzu Tai, Matthew Ho et al. (5 authors)
Experimental Hematology and Oncology
Open Access
Published: Jul 2017
34 citations
34 citations
2657 days before retraction
Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma
Klaus Podar, Martin Pecherstorfer
Expert Opinion on Pharmacotherapy
Published: Jun 2017
8 citations
8 citations
2689 days before retraction
Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma
Xiaoyan Feng, Li Zhang, Chirag Acharya et al. (9 authors)
Clinical Cancer Research
Open Access
Published: Mar 2017
225 citations
225 citations
2791 days before retraction
Monoclonal antibody therapy in multiple myeloma
Cyrille Touzeau, Philippe Moreau, Charles Dumontet
Leukemia
Published: Feb 2017
61 citations
61 citations
2804 days before retraction
Paper citing SAR650984 directly induces multiple myeloma cell d...
Unknown Authors
Unknown Journal
Published: Feb 2017
2807 days before retraction
Immunotherapy for the treatment of multiple myeloma
Sung‐Hoon Jung, Hyunju Lee, Manh-Cuong Vo et al. (5 authors)
Critical Reviews in Oncology/Hematology
Published: Jan 2017
29 citations
29 citations
2825 days before retraction
Safety issues and management of toxicities associated with new treatments for multiple myeloma
Annamaria Brioli, Lars‐Olof Mügge, Andreas Hochhaus et al. (4 authors)
Expert Review of Hematology
Published: Jan 2017
10 citations
10 citations
2828 days before retraction
Efficacy and safety of elotuzumab for the treatment of multiple myeloma
Maria Gavriatopoulou, Evangelos Terpos, Efstathios Kastritis et al. (4 authors)
Expert Opinion on Drug Safety
Published: Jan 2017
6 citations
6 citations
2845 days before retraction
Antibody mimicry, receptors and clinical applications
Alberto L. Horenstein, Antonella Chillemi, Valeria Quarona et al. (10 authors)
Human Antibodies
Published: Dec 2016
13 citations
13 citations
2856 days before retraction
Advances and practical use of monoclonal antibodies in multiple myeloma therapy
Hans C. Lee, Donna M. Weber
Hematology
Open Access
Published: Dec 2016
5 citations
5 citations
2881 days before retraction
Immune Therapies in Multiple Myeloma
Shaji Kumar, Kenneth C. Anderson
Clinical Cancer Research
Published: Nov 2016
62 citations
62 citations
2899 days before retraction
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
Jesús F. San Miguel, Hermann Einsele, Philippe Moreau
Advances in Therapy
Open Access
Published: Sep 2016
21 citations
21 citations
2947 days before retraction
Immunotherapies targeting CD38 in Multiple Myeloma
Djordje Atanackovic, Mary Steinbach, Sabarinath Venniyil Radhakrishnan et al. (4 authors)
OncoImmunology
Open Access
Published: Aug 2016
41 citations
41 citations
3000 days before retraction
Quick Stats
Total Citations:
213
Years Since Retraction:
1.1 year
Open Access:
Yes
Last Checked:
Jul 24, 2025